Verve raises $148M via public stock offering, private placement with Eli Lilly (corrected)
After releasing the first-ever results of an in vivo base editing therapy in humans, Verve Therapeutics has priced a public offering of 12.5 million shares …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
